Abstract

Currently, one of the key challenges in the pharmaceutical industry is the transformation of traditional batch production methods into robust continuous processes with the intention of reducing manufacturing costs and time and improving product quality. Crystallization is by far the most important purification technology in Pharma, as more than 80% of the active pharmaceutical ingredients (API) require at least one crystallization step. A successful crystallization process requires tight control over crystal size, shape and polymorphic purity. A rigorous and systematic methodology is presented to design and optimize multistage combined cooling and antisolvent continuous (mixed-suspension, mixed-product removal- MSMPR) crystallizers. The crystallization of acetylsalicylic acid (API) in ethanol (solvent) and water (anti-solvent) is used as a case study. A predictable and validated mathematical model of the system, which consists of a one-dimensional population balance model, was used to develop several optimizations strategies. Firstly, the attainable region of the mean particle size was determined for both minimum and maximum attainable crystal size. The method helped identify the most suitable number of stages and total residence time or volume for a cascade of continuous crystallizers. This was followed by a steady state optimization which helped determine the optimal operating temperatures and antisolvent flowrates. To minimize the startup time, a series of dynamic optimization strategies were implemented, assuming starting from empty vessels. The optimal dynamic profiles of the temperature and antisolvent flow rate, at different crystallization steps, were identified using a systematic and rigorous approach allowing a reduction in the startup time by 31%.

Highlights

  • Continuous manufacturing is increasingly seen as the most flexible and viable option for the pharmaceutical industry [1]

  • ASA in ethanol and water, the solubility of the active pharmaceutical ingredients (API) decreases as the antisolvent weight ratio increases from 25% to 70%

  • The constraint C4 ensures that the temperature in the (i + 1)th stage is always lower or equal to the temperature of the ith stage, which prevents undersaturated conditions and helps avoid heating which may lead to the dissolving the API crystals

Read more

Summary

Introduction

Continuous manufacturing is increasingly seen as the most flexible and viable option for the pharmaceutical industry [1]. Continuous pharmaceutical campaigns are anticipated to have short operating windows [2]. This makes the impact of startup and shut down extremely important in both cost of production and environmental impact. To address some of these key issues, the next-generation pharmaceutical plants require systematic, rigorous and robust optimal strategies for process design, operation, and control for single processes and integrated plants [2]. Crystallization is widely used in the pharmaceutical industry for its outstanding efficiency and economic performance in purifying active pharmaceutical ingredients (API). The quality of the final product is commonly determined by the crystal size distribution, shape, and purity, which impact

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call